LUNDBECK WORLDWIDE Global About us Disease areas Psychiatry and neurology Products Research and development Publications Policy for scientific publications and responsible clinical trial data sharing Become a clinical study investigator Investor Careers CSR Media Policy for scientific publications and responsible clinical trial data sharing Print Share Lundbeck’s mission is to improve the quality of life of people suffering from psychiatric and neurological disorders. As a pharmaceutical company, Lundbeck considers the sharing of information from company-sponsored clinical trials to be an important part of fulfilling this mission. Lundbeck publishes results from our research and clinical studies in scientific journals and presents these results at scientific conferences. Lundbeck also discloses clinical trial information and result summaries in public registries and share clinical data. The Lundbeck policy for scientific publications and responsible clinical data sharing covers all scientific publications originated or sponsored by H. Lundbeck A/S or affiliates. What is published Disclosure of clinical study information Publications from Clinical Research Clinical data sharing Lundbeck encourages publication of the results from research and discovery and from clinical studies of its products and drug development candidates, irrespective of whether the results are positive or negative, and acknowledges a special obligation to publish data related to patient safety. Per EFPIA/PhRMA´s commitment, Lundbeck will submit for publication the results of all Lundbeck-sponsored phase III clinical studies and results of any other clinical studies of significant medical importance, primarily in peer-reviewed journals, or as abstracts, posters, or other presentations at scientific meetings. Publication activities will be undertaken responsibly and ethically to ensure that all relevant information is communicated clearly and in a timely manner. Wherever possible, manuscripts will be submitted no later than 18 months after study completion for approved products. This also applies to drug development compounds for which development has been discontinued. The timing of nonclinical publications may take into consideration intellectual property rights as well as legislation and current national practices in patent law. When entering into research and development collaborations, it is Lundbeck’s commitment to maintain ethical and transparent publication practices, which is in accordance with Good Publication Practice 3 (www.ismpp.org/gpp3). Confidentiality Lundbeck respects the privacy of the relationship between patients and healthcare professionals and is committed to ensuring that the process of scientific publication and clinical trial data sharing do not breach patient confidentiality. Cookie Policy Page last modified 12 October 2015 Phone | Fax Sitemap | Contact us | Disclaimer and privacy statement Follow us on yYouTube tTwitter iLinkedIn